DaVita Inc. (NYSE:DVA) Stock Holdings Reduced by 8 Knots Management LLC

8 Knots Management LLC decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 1.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 680,882 shares of the company's stock after selling 9,840 shares during the quarter. DaVita accounts for about 10.2% of 8 Knots Management LLC's holdings, making the stock its 4th biggest position. 8 Knots Management LLC owned about 0.83% of DaVita worth $101,826,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Te Ahumairangi Investment Management Ltd increased its holdings in DaVita by 1.0% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 48,137 shares of the company's stock valued at $7,846,000 after acquiring an additional 500 shares in the last quarter. Tidal Investments LLC grew its position in shares of DaVita by 45.2% in the third quarter. Tidal Investments LLC now owns 5,688 shares of the company's stock valued at $932,000 after purchasing an additional 1,771 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of DaVita by 134.6% during the 3rd quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock worth $8,885,000 after purchasing an additional 31,502 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after buying an additional 169 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Up 0.8 %

DVA opened at $140.64 on Tuesday. The stock has a market capitalization of $11.25 billion, a price-to-earnings ratio of 13.09, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. DaVita Inc. has a 12 month low of $131.27 and a 12 month high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50-day moving average of $146.22 and a two-hundred day moving average of $155.10.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on shares of DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.